Arcturus CSO Chivukula sells shares worth $5,130 By Investing.com

San Diego-based Arcturus Therapeutics (NASDAQ:) Holdings Inc. (NASDAQ:ARCT) reported that its Chief Scientific Officer and Chief Operating Officer, Chivukula Pad, sold shares in the company. The transaction, which took place on June 5, 2024, involved the sale of 114 shares of common stock at a price of $45.00 per share, totaling $5,130.

The sale was conducted in accordance with a prearranged 10b5-1 trading plan, which allows company insiders to set up a predetermined plan to sell stocks at a time when they are not in possession of material non-public information. This regulatory tool is designed to help insiders avoid allegations of insider trading.

Following the sale, Chivukula Pad holds a total of 447,334 shares in Arcturus, a company that specializes in pharmaceutical preparations. The company has not made any additional comments on the transaction.

Investors and followers of Arcturus Therapeutics often pay close attention to insider sales as they may provide insights into an insider’s view of the company’s current valuation and future prospects. However, it is important to note that there could be various reasons for an insider to sell shares, and such transactions do not necessarily indicate a negative outlook.

For those interested in the specifics of the transaction, the company has indicated a willingness to provide full information regarding the number of shares sold at the price upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer.

Arcturus Therapeutics Holdings Inc. continues to operate from its headquarters in San Diego, California, focusing on the development of novel pharmaceutical therapies.

In other recent news, Arcturus Therapeutics has reported encouraging interim results from a Phase 1b trial of ARCT-032, an inhaled mRNA therapeutic for cystic fibrosis. The trial demonstrated a generally safe profile and an average increase of +4.0% in forced expiratory volume, a key measure of lung function, five days after the second dose. Investment firms Piper Sandler and Citi have retained their Overweight and Buy ratings on Arcturus, respectively, while awaiting additional data from the company’s cystic fibrosis program.

Arcturus has also been making progress with its vaccine and flu programs, including a substantial order of approximately 4 million doses of its Kostaive vaccine in Japan. The company anticipates its Arcalis manufacturing facility to be operational in the third quarter of 2024. However, despite a strong cash position and expectations of future milestone payments, Arcturus reported a net loss of $26.8 million for the first quarter of 2024. These are among the recent developments in the company’s journey.

InvestingPro Insights

Amidst the recent insider transaction at Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), investors may find it beneficial to consider the company’s financial health and market performance. Arcturus holds more cash than debt on its balance sheet, which can be a signal of financial stability and may reassure investors about the company’s ability to fund its operations and strategic initiatives.

Arcturus Therapeutics also boasts impressive gross profit margins, with the last twelve months as of Q1 2024 showing a margin of 87.19%. This indicates a strong ability to control costs relative to revenue, an important factor for investors assessing the company’s profitability potential.

However, it is notable that the company’s stock price has experienced significant volatility, accompanied by a large price uptick over the last six months, with a 77.35% total return. This could attract investors looking for growth stocks, but it also suggests a need for caution due to potential market fluctuations.

For those considering a deeper analysis of Arcturus Therapeutics, InvestingPro offers additional insights, with a total of 15 InvestingPro Tips available for the company. These tips range from earnings revisions by analysts to the company’s profitability outlook and stock performance over various periods. Access to these tips can be found at https://www.investing.com/pro/ARCT, and readers can use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.